Analytics

Pursuant to the President’s order, by 2018, 90% of the drugs on the VED list will have to be provided for by local manufacturers. As at the end of H116, import substitution accounted for 76%. Under the Seven Diseases program, the share of local drug grew from 4.6% in 2011 to 35% in 2015. This data was cited by Olga Kolotilova,…

The innovation share in the total drug consumption is just about 12% in value terms. An absolute majority of innovative drugs on the Russian market are of foreign origin; the share of local innovative pharmaceuticals is still insignificant. Experts note that innovative medicinal products are basically not considered a priority…

Research teams of the Siberian State Medical University and Lomonosov Moscow State University are nearing completion of preclinical trials of an antihypertensive drug. These trials were funded within the framework of the Federal Target Program Pharma-2020. The trials demonstrated that the drug was nontoxic and was effective over…

From January 1st, 2017, the status of local products will be assigned to drugs manufactured in Russia cumulatively for finished dosage form production and packaging stages. Pursuant to the Russian Government Resolution of 30.11.2015 # 1289 (the so-called “odd-man-out” regulation), packaging is enough to receive the local product…

RNC Pharma analyzed potential effects of a ban on cooking salt and sea water imports to Russia. The experts stated that, as a minimum, three foreign companies and one Russian manufacturer were in the risk group. To remind: from November 1st, 2016, commodity sub-item 250100 that constitutes the framework for sea water and sea water-based…

In November, the Russian MoH will be receiving HIV drug applications for the treatment of HIV, HBV, and HCV infected patients from sub-Federal entities. This information was released at the press conference within the framework of the 1st All-Russia’s GMP conference by Elena Maksimkina, Director of the Department for Drug Provision…

The market grew 8.2% in rubles but lost 4.4% of its volume. The value decline was more pronounced in USD (-32% vs. 2014). Market downfall is inversely related to USD-ruble exchange rate growth in 2015 (+59% vs. 2014). Drug prices grew an average of 10.3% in rubles, which is lower than the 12.91% inflation for the market as a whole.…

The market will function with some limitations starting January 1. Most documents are already in place, and all necessary agreements, such as the provision “On Adopting Marking of Medicinal Products”, will be signed before the end of the year. Manufacturers will need to have their product registration certificates validated for…